MedCity News November 25, 2025
Abbott’s $23 billion acquisition of Exact Sciences positions the company to become a major player in cancer diagnostics. Experts think the deal makes strategic sense, as it offers higher margins and a broader commercial scale — but questions remain about long-term growth amid rising competition and the challenges of integrating a patient-focused, tech-heavy business.
Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.
Experts view the deal as a bold, long-term play that expands Abbott’s portfolio in the high-growth area of diagnostics, as well as complements its existing commercial and regulatory strengths.
Abbott’s acquisition...
Today's Sponsors
Today's Sponsor